SCHEMBL3923741

SCHEMBL3923741

O=c1[nH]cncc1-c1ccc(OCc2ccccc2)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.49
ERN1 O75460 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
PRMT5 O14744 1/20 0.42
S1PR5 Q9H228 1/20 0.42
MET P08581 1/20 0.42
FEN1 P39748 2/20 0.41
CTSA P10619 1/20 0.41
IP6K1 Q92551 1/20 0.41
PTGER1 P34995 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
SLK Q9H2G2 2/20 0.40
STK10 O94804 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
FFAR1 O14842 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2285730 0.80 MET (0.62) ERN1PRMT5S1PR5METFEN1
SCHEMBL6641884 0.77 IDO1 (0.60) IDO1ADRA1DADRA1AADRA1BIP6K1
SCHEMBL3915575 0.76 GRK2 (0.45) IDO1ERN1S1PR5METFEN1
SCHEMBL30046945 0.76 KDM4E (0.51) ERN1PRMT5S1PR5FEN1CTSA
SCHEMBL24363273 0.75 ERN1 (0.50) ERN1PRMT5S1PR5FEN1CTSA
SCHEMBL3986972 0.74 ERN1 (0.46) ERN1PRMT5S1PR5METFEN1
SCHEMBL24363066 0.74 ERN1 (0.41) IDO1ERN1PRMT5S1PR5FEN1
SCHEMBL3917605 0.73 CYP11B1 (0.47) S1PR5FEN1CYP3A4CYP2C9
SCHEMBL8619252 0.73 ERN1 (0.53) ERN1S1PR5CTSAPTGER1FFAR1
SCHEMBL21162496 0.73 ERN1 (0.59) ERN1S1PR5CTSAFFAR1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 IDO1 1283/4885ERN1 2751/4885ADRA1D 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.